Neuroprotective Effects of Bis(7)-tacrine in a Rat Model of Pressure-Induced Retinal Ischemia

被引:0
作者
Jing-bo Li
Zhi-gang Lu
Li Xu
Qi Wang
Zu-hai Zhang
Jia-hua Fang
机构
[1] Yangtze University,Department of Ophthalmology, First Hospital of Jingzhou
[2] First Hospital of Jingmen,Department of Neurology
来源
Cell Biochemistry and Biophysics | 2014年 / 68卷
关键词
Bis(7)-tacrine; Retina; Ischemia–reperfusion; Glaucoma; Apoptosis; Rat;
D O I
暂无
中图分类号
学科分类号
摘要
The retinal ischemia–reperfusion model has been studied extensively and is an ideal animal model for studying clinical situations such as acute glaucoma and optic neuropathy. Our previous reports showed that bis(7)-tacrine had neuroprotective effects against glutamate-induced retinal ganglion cells damage through the drug’s anti-NMDA receptor effects. Here, we investigated whether bis(7)-tacrine protects the retina from ischemic injury in a rat model. Retinal ischemia was induced by raising the intraocular pressure to 120 mmHg for 90 min. Rats received intraperitoneal injections of 0.2 mg/kg bis(7)-tacrine or saline at 30 min before ischemia, and then twice a day after retinal ischemia. Morphometric evaluation showed that bis(7)-tacrine dramatically reduced the retinal damage compared with the control group. Moreover, bis(7)-tacrine suppressed ischemia-induced reductions in a- and b-wave amplitudes of electroretinography. Protein levels of p53, the tumor suppressor gene known to induce apoptosis, were increased after ischemic injury, and treatment with bis(7)-tacrine reduced the expression of the protein. Our results suggest that bis(7)-tacrine has a neuroprotective effect against ischemic injury in the rat retina, possibly through the drug’s anti-apoptotic effects. Bis(7)-tacrine may potentially be useful as a therapeutic drug in the management of ischemic retinal diseases.
引用
收藏
页码:275 / 282
页数:7
相关论文
共 212 条
[1]  
Quigley HA(2006)The number of people with glaucoma worldwide in 2010 and 2020 British Journal of Ophthalmology 90 262-267
[2]  
Broman AT(2012)Rationale for the use of multifunctional drugs as neuroprotective agents for glaucoma Neural Regeneration Research 7 313-318
[3]  
Fang JH(2007)Pharmacological neuroprotection for glaucoma Drugs 67 725-759
[4]  
Jiang FG(2002)Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study Experimental Eye Research 74 181-189
[5]  
Li JB(2011)Alzheimer’s disease and glaucoma: imaging the biomarkers of neurodegenerative disease International Journal of Alzheimer’s Disease 2010 793931-1559
[6]  
Zhu YH(2009)Alzheimer’s disease and glaucoma: is there a causal relationship? British Journal of Ophthalmology 93 1557-137
[7]  
Chidlow G(2002)Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease American Journal of Ophthalmology 133 135-3
[8]  
Wood JP(2009)Multifunctional drugs as neurotherapeutics Neurotherapeutics 6 1-359
[9]  
Casson RJ(2011)The emergence of designed multiple ligands for neurodegenerative disorders Progress in Neurobiology 94 347-164
[10]  
Lafuente MP(2008)Bis(7)-tacrine, a promising anti-Alzheimer’s dimer, affords dose- and time-dependent neuroprotection against transient focal cerebral ischemia Neuroscience Letters 439 160-335